Fresh Tracks Therapeutics Announces Hearing Date and Notice of Proposed Consent Judgement Regarding Dissolution of Company
Fresh Tracks Therapeutics (FRTX) announced that the Delaware Court of Chancery has scheduled a hearing for January 17, 2025, to consider a proposed Consent Judgment in the case of David R. McAvoy versus Fresh Tracks. If approved, a custodian will be appointed to dissolve the company and wind up its affairs under Delaware law.
The company has notified or will notify all stockholders of record as of November 20, 2024, about the Notice of Proposed Consent Judgment via email and/or first-class mail. Stockholders from the record date are invited to attend the hearing, with full details provided in the Notice.
Fresh Tracks Therapeutics (FRTX) ha annunciato che il Tribunale di Chancery del Delaware ha programmato un'udienza per il 17 gennaio 2025, per esaminare una proposta di Sentenza di Consenso nel caso di David R. McAvoy contro Fresh Tracks. Se approvata, verrà nominato un custode per sciogliere la società e chiudere i suoi affari secondo la legge del Delaware.
La società ha notificato o notificherà a tutti gli azionisti di registro al 20 novembre 2024, riguardo al Notifica della Proposta di Sentenza di Consenso tramite email e/o posta di prima classe. Gli azionisti dalla data di registrazione sono invitati a partecipare all'udienza, con tutti i dettagli forniti nella Notifica.
Fresh Tracks Therapeutics (FRTX) anunció que el Tribunal de Chancery de Delaware ha programado una audiencia para el 17 de enero de 2025, para considerar un proyecto de Sentencia de Consentimiento en el caso de David R. McAvoy contra Fresh Tracks. Si se aprueba, se nombrará un custodio para disolver la empresa y liquidar sus asuntos bajo la ley de Delaware.
La empresa ha notificado o notificará a todos los accionistas de registro al 20 de noviembre de 2024, sobre el Aviso de Propuesta de Sentencia de Consentimiento por correo electrónico y/o correo de primera clase. Se invita a los accionistas de la fecha de registro a asistir a la audiencia, con todos los detalles proporcionados en el Aviso.
Fresh Tracks Therapeutics (FRTX)는 델라웨어 총회가 2025년 1월 17일에 데이비드 R. 맥어보이 대 Fresh Tracks 사건의 제안된 동의 판결에 대한 심리를 진행한다고 발표했습니다. 만약 승인을 받게 되면, 관리인이 назнач되어 회사를 해산하고 델라웨어 법에 따라 사업을 정리하게 됩니다.
회사는 2024년 11월 20일 기준으로 모든 주주에게 동의 판결 제안 통지에 대해 이메일 및/또는 1급 우편으로 통지했거나 통지할 예정입니다. 기록된 날짜의 주주들은 청문회에 참석할 수 있으며, 모든 세부 사항은 통지서에 제공됩니다.
Fresh Tracks Therapeutics (FRTX) a annoncé que la Cour de Chancery du Delaware a fixé une audience au 17 janvier 2025 pour examiner un projet de jugement par consentement dans l'affaire David R. McAvoy contre Fresh Tracks. Si cela est approuvé, un administrateur sera nommé pour dissoudre la société et liquider ses affaires conformément à la loi du Delaware.
La société a notifié ou notifiera tous les actionnaires enregistrés au 20 novembre 2024 au sujet de l'Avis de Projet de Jugement par Consentement par e-mail et/ou par courrier de première classe. Les actionnaires à la date d'enregistrement sont invités à assister à l'audience, avec tous les détails fournis dans l'Avis.
Fresh Tracks Therapeutics (FRTX) gab bekannt, dass das Gericht von Delaware für den 17. Januar 2025 eine Anhörung anberaumt hat, um einen vorgeschlagenen Konsensurteil im Fall David R. McAvoy gegen Fresh Tracks zu prüfen. Bei Genehmigung wird ein Verwalter ernannt, um das Unternehmen aufzulösen und dessen Angelegenheiten gemäß dem Recht von Delaware abzuwickeln.
Das Unternehmen hat alle Aktionäre, die zum 20. November 2024 im Handelsregister eingetragen sind, über die Bekanntmachung des vorgeschlagenen Konsensurteils per E-Mail und/oder Einschreiben benachrichtigt oder wird dies tun. Aktionäre ab dem Stichtag sind eingeladen, an der Anhörung teilzunehmen, wobei alle Einzelheiten in der Bekanntmachung enthalten sind.
- None.
- Company faces potential dissolution pending court approval
- Shareholders face potential total loss of investment if dissolution is approved
In accordance with a Court-approved scheduling order, Fresh Tracks has sent or will send to each of its stockholders, as of the record date of November 20, 2024, by electronic mail and/or first class
Fresh Tracks Therapeutics, Inc.
Investor Contact:
Albert N. Marchio II
Chief Executive Officer and Chief Financial Officer
amarchio@frtx.com
View original content:https://www.prnewswire.com/news-releases/fresh-tracks-therapeutics-announces-hearing-date-and-notice-of-proposed-consent-judgement-regarding-dissolution-of-company-302324542.html
SOURCE Fresh Tracks Therapeutics, Inc.
FAQ
When is Fresh Tracks Therapeutics (FRTX) dissolution hearing scheduled?
What is the record date for FRTX stockholders regarding the dissolution notice?
What will happen if the Consent Judgment for FRTX is approved?
